文献速递胃肠外科围术期管理与 ERAS

目标试验模拟比较内镜袖状胃成形术与袖状胃切除术后6个月体重变化

Target Trial Emulation of 6-Month Weight Change after Endoscopic Sleeve Gastroplasty and Sleeve Gastrectomy: A Retrospective Cohort Study.
PubMed 文献 · J Am Coll Surg · 2026-06-18

该回顾性队列研究基于2023年MBSAQIP随访文件,采用目标试验模拟方法,将417例ESG与3336例SG按1:8匹配,比较6个月体重变化及临床结局。结果显示SG减重更显著(-18.51% vs -12.33%,p<0.001),且合并症结局更优,但ESG再入院和再手术率更高。

要点

  • SG术后6个月体重下降百分比大于ESG(-18.51% vs -12.33%,p<0.001)。
  • ESG的30天和6个月再入院率(3.8% vs 1.6%)及再手术率(1.0% vs 0.3%)高于SG。
  • ESG减重效果具有临床意义且绝对不良事件率低,但选择术式时需权衡再入院风险。

核心结论

  • 在目标试验模拟中,SG与6个月减重更多及短期合并症结局更优相关。
  • ESG虽减重有临床意义且绝对不良事件率低,但再入院和再手术率较高。

研究设计与样本

  • 回顾性队列研究,使用2023年MBSAQIP随访文件。
  • 采用目标试验模拟方法,按年龄、性别、种族、糖尿病、高血压、心血管合并症及最高术前BMI进行1:8最近邻匹配。
  • 匹配队列共3753例,其中ESG 417例,SG 3336例。
  • 主要分析采用逆概率删失加权回归处理6个月体重缺失。

主要发现

  • 6个月时SG体重变化百分比为-18.51%±7.98,ESG为-12.33%±6.96(p<0.001)。
  • 逆概率删失加权回归中,SG仍与更大体重变化百分比相关(ESG系数+7.40;95%CI 6.59至8.21)。
  • 两组绝对不良事件率均低。
  • SG合并症结局更有利。
  • ESG与更高的30天和6个月再入院率(3.8% vs 1.6%)及再手术率(1.0% vs 0.3%)相关。

临床怎么用

  • 术式选择及患者咨询时需考虑SG减重更优但ESG再入院和再手术风险更高。
  • ESG可作为减重有临床意义且绝对不良事件率低的微创选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endoscopic sleeve gastroplasty (ESG) offers a less invasive alternative to sleeve gastrectomy (SG) while preserving gastric anatomy; however, comparative effectiveness data from large real-world cohorts remain limited. Using the 2023 MBSAQIP follow-up file, we compared short-term weight-loss and clinical outcomes after ESG and SG. STUDY DESIGN: ESG and SG cases were identified from the 2023 MBSAQIP follow-up file. Using target trial emulation methodology, patients underwent 1:8 nearest-neighbor matching on age, sex, race, diabetes, hypertension, cardiovascular comorbidity, and highest preoperative BMI. The primary outcome was percent weight change from highest preoperative weight to 6 months. The primary analysis used inverse probability of censoring weighting regression to account for missing 6-month weights. Secondary outcomes included 30-day adverse events and 6-month comorbidity and laboratory outcomes. RESULTS: The matched cohort included 3,753 patients (ESG, 417; SG, 3,336). At 6 months, SG achieved greater weight loss than ESG (-18.51% ± 7.98 vs -12.33% ± 6.96; p < 0.001). In inverse probability of censoring weighting regression, SG remained associated with greater percent weight change (ESG coefficient +7.40; 95% CI, 6.59 to 8.21). Absolute adverse-event rates were low in both groups. SG demonstrated more favorable comorbidity outcomes, whereas ESG was associated with higher 30-day and 6-month readmission (3.8% vs 1.6%) and reoperation (1.0% vs 0.3%) rates. CONCLUSIONS: In this target trial emulation of a national bariatric registry, SG was associated with greater 6-month weight loss and more favorable short-term comorbidity outcomes than ESG. Although ESG produced clinically meaningful weight reduction with low absolute adverse-event rates, its higher readmission and reoperation rates should be considered during procedure selection and patient counseling.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Leslie ZD, Bazerbachi F, Dirweesh A, et al. Target Trial Emulation of 6-Month Weight Change after Endoscopic Sleeve Gastroplasty and Sleeve Gastrectomy: A Retrospective Cohort Study. J Am Coll Surg. 2026. PMID: 42307476. doi:10.1097/XCS.0000000000002072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。